GLAXOSMITHKLINE plans to establish its third center for vaccine research and development in Rockville, Md. The site follows existing R&D centers in Rixensart, Belgium and Siena, Italy, which GSK acquired from Novartis in March.
The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.
